Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice

129Citations
Citations of this article
223Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Transplantation of glial-rich neural progenitors has been demonstrated to attenuate motor neuron degeneration and disease progression in rodent models of mutant superoxide dismutase 1 (SOD1)-mediated amyotrophic lateral sclerosis (ALS). However, translation of these results into a clinical setting requires a renewable human cell source. Here, we derived glial-rich neural progenitors from human iPSCs and transplanted them into the lumbar spinal cord of ALS mouse models. The transplanted cells differentiated into astrocytes, and the treated mouse group showed prolonged lifespan. Our data suggest a potential therapeutic mechanism via activation of AKT signal. The results demonstrated the efficacy of cell therapy for ALS by the use of human iPSCs as cell source. © 2014 The Authors.

Cite

CITATION STYLE

APA

Kondo, T., Funayama, M., Tsukita, K., Hotta, A., Yasuda, A., Nori, S., … Inoue, H. (2014). Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. Stem Cell Reports, 3(2), 242–249. https://doi.org/10.1016/j.stemcr.2014.05.017

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free